Background In recent years, longitudinal studies of Alzheimer's disease (AD) have been
successively concluded. Our aim is to determine the efficacy of amyloid‐β (Aβ) PET in …

Introduction We studied whether fully automated Elecsys cerebrospinal fluid (CSF)
immunoassay results were concordant with positron emission tomography (PET) and …

Background Soluble amyloid-β (Aβ) oligomers are the major toxic substances associated
with the pathology of Alzheimer's disease (AD). The ability to measure Aβ oligomer levels in …

Importance Visual assessment of amyloid positron emission tomographic (PET) images has
been approved by regulatory authorities for clinical use. Several immunoassays have been …

Alzheimer's disease (AD), Parkinson's disease (PD), frontotemporal dementia (FTD),
amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), and prion diseases have a …

The number of patients with Alzheimer's disease (AD) is rapidly increasing in Asia.
Mutations in the amyloid protein precursor (APP), presenilin-1 (PSEN1), and presenilin-2 …

Background β-amyloid (Aβ) positron emission tomography (PET) imaging is currently the
only Food and Drug Administration-approved method to support clinical diagnosis of …

Cerebrospinal fluid (CSF) β-amyloid (Aβ) is important for early diagnosis of Alzheimer's
disease (AD). However, the cohort distributions and cut-off values have large variation …

Introduction We examined the association between cerebrospinal fluid (CSF)‐derived
biomarkers of Alzheimer's disease and neuropsychiatric symptoms (NPS) in older non …

Abstract Background Widespread implementation of Alzheimer's disease biomarkers in
routine clinical practice requires the establishment of standard operating procedures for pre …